On May 12, 2026 Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune disease, reported that the first patient has been dosed in the NEO-CYT study, a randomized, investigator-initiated neoadjuvant Phase 1b trial evaluating MDNA11, Medicenna’s long-acting, "beta-enhanced not-alpha" IL-2 Superkine, in combination with nivolumab, with or without ipilimumab, in patients with high-risk, surgically resectable Stage III cutaneous melanoma at up to 12 centers in Italy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Neoadjuvant therapy has demonstrated that the timing of immunotherapy can be critical," said Professor Paolo A. Ascierto, Lead Principal Investigator of NEO-CYT. "Treating patients while the tumor is still present may generate deeper and more durable immune responses. NEO-CYT is designed to investigate whether MDNA11, a next-generation IL-2 Superkine, may potentiate the immune activity of nivolumab, with or without ipilimumab, leading to improved pathologic responses and potentially higher cure rates in patients with resectable, high-risk melanoma."
The NEO-CYT study is designed to evaluate MDNA11 as neoadjuvant immunotherapy before curative-intent surgery in earlier-stage melanoma patients whose immune systems may be more amenable to immunotherapy and more likely to benefit from treatment. MDNA11 will be evaluated in combination with nivolumab, with or without ipilimumab, with major pathologic response as a primary endpoint, which is considered predictive of long-term survival outcomes.
NEO-CYT is sponsored by the non-profit Melanoma Foundation, Fondazione Melanoma Onlus and is led by Professor Paolo A. Asciert of the Istituto Nazionale Tumori IRCCS ‘Fondazione G. Pascale.’ Under the terms of the clinical trial collaboration, Fondazione Melanoma Onlus is the Sponsor and Medicenna is supplying the study medications.
"Dosing the first patient in the NEO-CYT study represents an important milestone in the continued clinical development of MDNA11 and expands our evaluation of this next-generation IL-2 Superkine into the neoadjuvant setting," said Dr. Nageatte Ibrahim, Chief Medical Officer of Medicenna. "MDNA11 has already demonstrated encouraging anti-tumor activity and a manageable safety profile in heavily pretreated patients with advanced metastatic cancers in the ongoing ABILITY-1 study. NEO-CYT allows us to evaluate MDNA11 earlier in the treatment paradigm, where the immune system may be more intact and where pathologic response can provide an early and rigorous signal of clinical activity. We are honored to collaborate with Fondazione Melanoma Onlus and Professor Ascierto on this important study."
MDNA11 is currently being evaluated in the Phase 1/2 ABILITY-1 study as both monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. In prior clinical updates, MDNA11 has demonstrated encouraging anti-tumor activity in heavily pretreated patients, including patients whose tumors progressed following immune checkpoint inhibitor therapy, alongside robust immune effector cell expansion and a manageable safety profile. NEO-CYT is intended to build on these findings by evaluating MDNA11 in an earlier-stage, potentially curative treatment setting.
About MDNA11
MDNA11 is a long-acting, ‘beta-enhanced not-alpha’ IL-2 Superkine specifically engineered to overcome the shortcomings of aldesleukin and other next generation IL-2 variants by preferentially activating immune effector cells (CD8+ T and NK cells) responsible for killing cancer cells, with minimal or no stimulation of immunosuppressive Tregs. These unique proprietary features of the IL-2 Superkine have been achieved by incorporating seven specific mutations and genetically fusing it to a recombinant human albumin scaffold to improve the pharmacokinetic (PK) profile and pharmacological activity of MDNA11 due to albumin’s natural propensity to accumulate in highly vascularized sites, in particular tumor and tumor draining lymph nodes. MDNA11 is currently being evaluated in the Phase 1/2 ABILITY-1 study as both monotherapy and in combination with pembrolizumab.
(Press release, Medicenna Therapeutics, MAY 12, 2026, View Source [SID1234665547])